Glassdoor is your resource for information about the Vacation & Paid Time Off benefits at Bristol Myers Squibb. Non-GAAP earnings and related EPS information are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of past or future operating results. hA 04Fq\GczC. though we are required to work bank holidays, Paid holidays for employees are always offered, they add weeks off at times. Key 2022 GAAP and non-GAAP line-item guidance assumptions are: The 2022 financial guidance excludes the impact of any potential future strategic acquisitions and divestitures, and any specified items that have not yet been identified and quantified. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today's research reports here >>>Bristol-Myers Squibb's shares . Bristol-Myers Squibb (NYSE: BMY) is a global biopharmaceutical company committed to discovering, developing, and delivering medicines that help patients prevail over serious diseases. Gordon Dyal & Co., LLC is serving as the exclusive financial advisor to Bristol Myers Squibb, and Kirkland & Ellis LLP is serving as legal counsel. Join scientists like Aparna's team, who have helped Bristol Myers Squibb establish a leadership position within hematology oncology therapies, doing interesting and meaningful work while transforming patients lives daily. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com or by using this link which becomes active 15 minutes prior to the scheduled start time and entering your information to be connected. Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, the companies said.. Such risks, uncertainties and other matters include, but are not limited to: increasing pricing pressures from market access, pharmaceutical pricing controls and discounting; changes to tax and importation laws and other restrictions in the United States, the European Union and other regions around the world that result in lower prices, lower reimbursement rates and smaller populations for whom payers will reimburse; changes under the 340B Drug Pricing Program; challenges inherent in new product development, including obtaining and maintaining regulatory approval; the companys ability to obtain and protect market exclusivity rights and enforce patents and other intellectual property rights; the possibility of difficulties and delays in product introduction and commercialization; the risk of certain novel approaches to disease treatment (such as CAR T therapy); industry competition from other manufacturers; potential difficulties, delays and disruptions in manufacturing, distribution or sale of products, including without limitation, interruptions caused by damage to the companys and the companys suppliers manufacturing sites; the impact of integrating the companys and Celgenes business and operations, including with respect to human capital management, portfolio rationalization, finance and accounting systems, sales operations and product distribution, pricing systems and methodologies, data security systems, compliance programs and internal controls processes; the risk of an adverse patent litigation decision or settlement and exposure to other litigation and/or regulatory actions; the impact of any healthcare reform and legislation or regulatory action in the United States and international markets; increasing market penetration of lower-priced generic products; the failure of the companys suppliers, vendors, outsourcing partners, alliance partners and other third parties to meet their contractual, regulatory and other obligations; regulatory decisions impacting labeling, manufacturing processes and/or other matters; the impact on the companys competitive position from counterfeit or unregistered versions of its products or stolen products; the adverse impact of cyber-attacks on the companys information systems or products, including unauthorized disclosure of trade secrets or other confidential data stored in the companys information systems and networks; the companys ability to execute its financial, strategic and operational plans; the companys ability to identify potential strategic acquisitions, licensing opportunities or other beneficial transactions; the companys dependency on several key products; any decline in the companys future royalty streams; the companys ability to effectively manage acquisitions, divestitures, alliances and other portfolio actions and to successfully realize the expected benefits of such actions; the companys ability to attract and retain key personnel; the impact of the companys significant additional indebtedness that it incurred in connection with the Celgene acquisition and the MyoKardia acquisition; political and financial instability of international economies and sovereign risk; interest rate and currency exchange rate fluctuations, credit and foreign exchange risk management; the impact of adverse outcomes in lawsuits, claims, proceedings and government investigations; the impact of our exclusive forum provision in our by-laws for certain lawsuits on our stockholders ability to obtain a judicial forum that it finds favorable for such lawsuits; issuance of new or revised accounting standards; and risks relating to public health outbreaks, epidemics and pandemics, including the impact of the COVID-19 pandemic on the companys operations. 3 floating holidays. 0000043468 00000 n The website may also contain certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. The actual financial impact of this transaction may differ from the expected financial impact described in this communication. 0000008533 00000 n Posted: October 12, 2021 Full-Time At Bristol Myers Squibb, we are inspired by a single vision - transforming patients' lives through science. Whether recruiting from academia or the commercial biopharma sector, Mihaela explains why a move to BMS is a great career move. We may use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. . I'm a new hire. (EPS) for full-year 2021 between $3.18 and $3.38, up from its previous forecast of a range of $3.12 to $3.32. Our work is challenging and you shouldn't have to go it alone. 0000043107 00000 n Deferred and current income taxes attributed to these items are also adjusted for considering their individual impact to the overall tax expense, deductibility and jurisdictional tax rates. The transaction is expected to be up to $0.08 per share dilutive to non-GAAP EPS in 2022 prior to any impact from an acquired in-process research and development charge based on final accounting treatment. "Bristol Myers Squibb is well positioned to build on our success in 2021 and continue to grow our company through the end of the decade." Giovanni Caforio Bristol Myers Squibb is also reaffirming its previously communicated 2020-2025 long-term targets: This financial guidance excludes the impact of any potential future strategic acquisitions and divestitures as well as any specified items as discussed under Use of Non-GAAP Financial Information. There is no reliable or reasonably estimable comparable GAAP measures for this non-GAAP financial guidance. Bristol Myers Squibb expects repotrectinib to be approved in the U.S. in the second half of 2023 and become a new standard of care for patients with ROS1-positive NSCLC in the first-line setting. No additional data or studies have been requested. Learn about joining our global team! 0000193438 00000 n Breakout Session - Bristol Myers Squibb Presents: The Future of Cancer Care: Transformative Innovation for All . No forward-looking statement can be guaranteed. 2021 was a pivotal year for our company as we achieved significant regulatory and clinical milestones and positioned the company to successfully renew our portfolio. Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Barclays Virtual Global Healthcare Conference, which will Shares of Bristol Myers Squibb Co. BMY, -0.22% sank 0.22% to $66.77 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX, Glassdoor is your resource for information about the Vacation & Paid Time Off benefits at Bristol Myers Squibb. Bristol-Myers Squibb Company (BMY) will begin trading ex-dividend on September 30, 2021. 0000006923 00000 n These items are excluded from non-GAAP earnings and related EPS information because the company believes they neither relate to the ordinary course of the companys business nor reflect the companys underlying business performance. Forward-looking statements in this communication should be evaluated together with the many uncertainties that affect Bristol Myers Squibbs business, particularly those identified in the cautionary factors discussion in Bristol Myers Squibbs Annual Report on Form 10-K for the year ended December 31, 2021, and its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and in Turning Point Therapeutics Annual Report on Form 10-K for the year ended December 31, 2021 and its subsequent Quarterly Reports on Form 10-Q , as well as other documents that may be filed by Bristol Myers Squibb or Turning Point Therapeutics from time to time with the SEC. By 1943, Squibb operated the largest penicillin production plant in the world in New Brunswick, New Jersey. No cons. I am ready to take up a new challenge and I would like to take this opportunity to put the knowledge and skills acquired during my career at the service of my new employer and future colleagues. Japan's Ministry of Health, Labour and Welfare also accepted the NDA for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis, pustular psoriasis and erythrodermic psoriasis. The benefit choices you make go into effect each January 1 (or on your date of eligibility, if later), and stay in effect through December 31, as long as you remain eligible for benefits. A replay of the conference call will be available beginning at 11:30 a.m. Bristol Myers Squibb Normal for industry. Bristol Myers Squibb is well positioned to build on our success in 2021 and continue to grow our company through the end of the decade. Join scientists like Aparna's team, who have helped Bristol Myers Squibb establish a leadership position within hematology oncology therapies, doing interesting and meaningful work while transforming patients lives daily. June 08, 2022 06:59 AM Eastern Daylight Time. Apr 2021 - Oct 2022 1 year 7 months. We are committed to following all laws regarding child labor, forced labor and freedom of association. Image Source: Zacks Investment Research. The variability of the specified items may have a significant and unpredictable impact on our future GAAP results. Whether its bringing more than a dozen key medicines to market since 2009, or expanding patient access to medicine, our commitment to patients inspires us and guides our actions as responsible corporate citizens. Media and Investor Relations: ir@tptherapeutics.com, Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company. Bristol-Myers Squibb has 9 holidays and 4 personal/floating holidays. The transaction supports Bristol Myers Squibbs medium- to long-term growth strategy with accretion to non-GAAP earnings per share (EPS) beginning in 2025. xref Research and development expenses decreased 30% to $2.6 billion in the quarter. Available to US-based employeesChange location. Learn about 2023 benefits. We may also use social media channels to communicate with our investors and the public about our company, our products and other matters, and those communications could be deemed to be material information. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. If you have $1,000 at the ready, pharmaceutical stock Bristol Myers Squibb *Stock Advisor returns as of June 7, 2021. Cautionary Statement Regarding Forward-Looking Statements. FDA MedWatch at 1-800-FDA-1088, and Celgene Corporation, a Bristol-Myers Squibb Company, at 1-888-423-5436. Connect with a more experienced colleague to be your sounding board and to help guide you forward.